The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
Desk
SSRIs, SNRIs, atypicals, novel mechanisms. The pipeline, the labels, the reimbursement.
The KOMET trial, posted September 24 and not yet recruiting, will test oral ketamine against oral midazolam in 220 adults at five Indian sites. The earlier blinded oral-ketamine trials identified here enrolled 81 patients or fewer, used different doses, comparators, and endpoints, and included one that missed its primary endpoint.
The open-label extension of Vistagen's fourth Phase 3 study of fasedienol, released Tuesday, showed four months of improvement on two standard anxiety scales in patients who knew they were taking the drug. The trial's placebo-controlled portion, reported in June, missed its primary and secondary endpoints, with the numbers narrowly favoring placebo. It is fasedienol's second consecutive placebo-controlled Phase 3 miss.
Xenon submitted an NDA for azetukalner in focal seizures built on two trials that separately produced the same result at the same dose. On the same day, it paused new enrollment in its depression and bipolar depression trials over a safety signal Phase 2 never showed, a study whose primary depression-severity endpoint had already missed significance in 2023.
FDA reclassified an amendment to NRx Pharmaceuticals' generic ketamine application from Major to Minor on September 15, moving the review's goal date to November 10. The company's own SEC filings show why the amendment became Major in the first place: a vial cap FDA flagged as a container-closure problem in August, after the application's original July 29 goal date had already passed.
LPCN 1154 failed its primary endpoint in the full analysis set of its first Phase 3 trial. Lipocine's case for running a second one rests on a post hoc analysis excluding a site where roughly 40 percent of treated participants had no detectable drug in their blood, a finding the company disclosed in stages: nothing in April, a quarterly filing's quantified detail in August, and a press-release number in September.
Adults in crisis have rapid-acting ketamine evidence behind them; adolescents in the emergency department have none. Two Canadian feasibility pilots, one of which stopped early, are the first attempt to find out whether that gap can even be studied.
AtaiBeckley shareholders approved the merger, and Eli Lilly completed the acquisition on September 11, confirmed directly in the company's own SEC filing. The upfront cash is fixed. The other $1 billion sits behind three separate milestones, and the two drug programs don't carry equal weight in how that money is structured.
TS-161 is now the third rationally designed 'safer ketamine' candidate to miss its primary efficacy endpoint in a pivotal trial. The logic behind each one was sound. None of them has yet shown that sound logic is enough.
Ket-BD is the first dedicated randomized trial testing ketamine specifically in treatment-resistant bipolar depression, a population researchers have avoided over fears of triggering mania. Ketamine beat a placebo-like sedative on depression scores. Almost half the patients also correctly guessed which drug they'd gotten.
A systematic review of ketamine trials for depression found urological symptoms in up to a quarter of patients, far below what's seen in recreational abuse. But most of those trials never ran long enough, or watched closely enough, to answer the question that matters as repeated dosing becomes standard practice.
Every antipsychotic on the market works by blocking dopamine receptors. Evenamide doesn't. Newron completed screening toward a 600-patient pivotal trial testing it as an add-on for patients who don't respond to current treatment, including those already on clozapine. Data isn't expected until early 2027, but the mechanism itself is the reason this trial is worth tracking now.
A new expert review lays out seltorexant's full case for treating depression with insomnia: positive Phase 3 data, a distinct mechanism, a clean safety record. Buried inside that same review is the one result that determines whether any of it matters commercially, and it's a loss.
A Washington University team solved six cryo-EM structures showing ketamine and PCP bound directly inside the same pocket opioid drugs occupy, not adjacent to it. The finding gives years of behavioral and pharmacological evidence linking ketamine to opioid receptors a direct molecular basis, and it revises a specific claim from the field's own foundational paper on the question.
Fibromyalgia sits entirely outside ketamine's labeled indications, and formulary and prior-authorization decisions for this off-label use have rested on studies of 34 patients or fewer. A new 92-patient retrospective with two years of follow-up is the largest and longest such dataset yet, and it shows both a durable benefit for some patients and a hard ceiling on how many respond at all.
A Karolinska Institutet team found that socially dominant mice, not subordinate ones, showed the greater behavioral disruption after chronic stress, and that a single ketamine dose reversed much of it. The result adds a specific, counterintuitive variable to a question this desk keeps circling: why ketamine's antidepressant response varies so much from one patient to the next.
Brenipatide, a Lilly incretin-class compound reported to be a dual GIP/GLP-1 agonist, was positioned for addiction and mood disorders. It is now in Phase 3 for major depression relapse prevention and alcohol use disorder, and in Phase 2 for bipolar disorder, smoking-cessation relapse prevention, opioid use disorder, and schizophrenia. That breadth is the story, not any single trial.
Tianeptine produces hippocampal brain activity that an established opioid drug also produces, and that naloxone blocks entirely. Ketamine, tested in the same experiment, does neither. The finding doesn't change tianeptine's regulatory status, but it gives the case for treating it as an opioid-mechanism drug pharmacological evidence to stand on, rather than a proposed threshold and a list of exposure cases alone.
SIMTRIYO's approval gives ADHD its first new mechanism in years, and gives Otsuka a second significant CNS win following its psychedelic-adjacent Transcend acquisition, following a rejection less than a year earlier in a different indication. The approval itself is not the whole story; the drug cannot reach patients until the DEA finishes scheduling it.
The Defense Department's adaptive platform trial, the efficient vehicle built to test the next generation of PTSD drugs after the MDMA rejection, has been suspended, master protocol and every arm. The registration explains it only as deferred. PTSD pharmacology, stuck on two-decade-old antidepressants, is left waiting again.
A multicentre trial reported that a single dose of esketamine around childbirth helps prevent postpartum depression. It arrived with a formal comment and author reply in the same issue, and the dispute lands on exactly the two problems the desk keeps flagging: a blind the drug's own side effects may have broken, and a benefit braided into pain relief.
A new review finds that at the doses used for mood disorders, ketamine mostly causes mild, transient liver enzyme bumps, with serious hepatotoxicity rare. The catch is in the fine print: the dangerous cases cluster at high cumulative exposure, which is exactly the direction expansion, maintenance dosing, and the off-label clinic boom are pushing toward.
Brenipatide, Lilly's CNS-optimized dual GIP/GLP-1 agonist, is now in trials across depression, bipolar disorder, alcohol use disorder, smoking, and schizophrenia. The new bipolar Phase 2 is one tile in a portfolio that answers a question this desk raised: whether the owner of the era's most valuable drug class would bring it into psychiatry. It would, comprehensively.
A target trial emulation examines esketamine in patients with cancer-related depression, with a survival endpoint. It is a genuinely new population for the drug. It is also a single observational cohort measuring the most confounded outcome there is, which is exactly why the result, whatever it shows, has to be read with discipline.
OCD is not depression. Different circuitry, possibly a different mechanism. A systematic review of ketamine in OCD marks the field taking the question seriously, but it synthesizes a small, preliminary literature. The real test is whether ketamine's effect holds up in a disorder built differently, and in the patients who most need it.
NIAAA opened Phase 1 trials of tirzepatide and suvorexant for alcohol use disorder in the same cycle, both probing the brain's reward circuitry. It is the addiction version of a pattern the desk keeps seeing, a neglected indication revived by federal repurposing of approved drugs. With one difference that matters commercially.
Obsessive-compulsive disorder still runs on SSRIs and clomipramine, the latter from the 1960s. A cluster of academic trials is testing repurposed drugs with mechanisms outside the serotonin paradigm. It is a research-interest revival, not a commercial pipeline, and the distinction is the story.
A federally funded Phase 2 will test hydroxynorketamine, the ketamine metabolite hypothesized to deliver the antidepressant effect without the dissociation or abuse risk. The idea has been contested for a decade, and the human data so far is not encouraging. The result bears on every clean-ketamine program in the pipeline.
In a single cycle, ketamine programs advanced in bipolar depression, anorexia, and postpartum depression, on top of the oral and deuterated reformulations already in the clinic. The breadth is real, and it says more about the economics of an off-patent molecule than about new biology.
Transcend's methylone is in Phase 3 for PTSD, holds FDA Breakthrough and priority-voucher status, and just drew a $1.2 billion acquisition from Otsuka. Its pitch is that it delivers the benefit of MDMA without the hallucinogenic experience that helped sink the MDMA application.
Bristol Myers is running a separate Phase 3 program, ADAGIO, for agitation in Alzheimer's, distinct from its psychosis trials. Agitation already has an approved treatment. So this is a challenge on safety, not a first move, and the data is years away.
A new multicentre trial adds to a decade of randomized studies testing the ketamine class against postpartum depression. They keep producing the same result: a real short-term signal on a screening scale, in a setting that confounds it, that fades before it counts.
ACP-211 is a deuterated form of R-norketamine that ACADIA is testing as a standalone pill in treatment-resistant depression. The framing is a direct contrast with Spravato. The mechanism carries the same questions that follow every ketamine-class drug.
The closest analog to a psychedelic approval is the one that already happened. Spravato took six years to reach $1 billion in annual revenue and is now Johnson & Johnson's fastest-growing neuroscience product. The launch curve has lessons for every program waiting on the voucher review window.
A cluster of papers in the June American Journal of Psychiatry adds evidence that ketamine's antidepressant and antisuicidal effects engage the mu-opioid receptor. That undercuts the clean-glutamate story the approved franchise was built on, and revives the abuse-liability question the field has tried to set aside.
Most of the recent antidepressant approvals are reformulations, recombinations, or rediscoveries of mechanisms the field had previously left behind. The volume of actually new pharmacology is much narrower than the press coverage suggests, and the structural reasons matter for sponsors planning the next wave.
A new antipsychotic mechanism reached the market as a monotherapy. Its adjunctive trial missed, the rival M4 drug failed outright, and the Alzheimer's readout slipped a year on data irregularities. The mechanism is real. Every bet built on top of it is still unproven.
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| Remlifanserin (formerly ACP-204)Alzheimer's disease psychosis | Acadia Pharmaceuticals | Phase 3 | Phase 2 portion of RADIANT narrowly missed its primary endpoint (p=0.0603); company plans to continue its two ongoing Phase 3 studies in ADP, without the 30 mg arm; FDA Fast Track granted July 2026; Phase 2 in Lewy body dementia psychosis ongoing |
| FasedienolSocial anxiety disorder (acute treatment) | Vistagen Therapeutics | Phase 3 | PALISADE-3 (Dec 2025) and PALISADE-4 (June 2026) did not meet their primary endpoints; Vistagen is preparing to meet FDA on a potential registrational path built on a single future multi-dose Phase 3; no new Phase 3 has started |
| Centanafadine (SIMTRIYO)ADHD (adults and children 6+, at least 20 kg) | Otsuka | Approved | FDA approval letter dated July 24, 2026 (first-in-class NDSRI); formal approval date awaits DEA's interim final scheduling notice (not yet published as of Oct 9, 2026); no marketing until then |
| Navacaprant (NMRA-140)Major depressive disorder | Neumora Therapeutics | Phase 3 | KOASTAL-2/-3 missed; development discontinued |
| Cobenfy (xanomeline-trospium)Schizophrenia | Bristol Myers Squibb | Approved | Approved for adults with schizophrenia (September 2024); adjunctive ARISE trial missed its primary endpoint (April 2025); Phase 3 trials continue in Alzheimer's psychosis, bipolar I and other indications |